Fig. 4.

Managing tumor heterogeneity. A VHH-based CAR targeting two epitopes of the same antigen. B CAR T-cell targeting novel antigens like SLAMF7 C. Co-infusion of two distinct CAR T-cells targeting different antigens. D CAR T-cell expression two distinct CARs targeting different antigens. E Bispecific CAR T-cells targeting two different antigens. Recognition of each target antigen leads to T-cell activation and tumor shrinkage